Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
The dopamine D(1) receptor is considered to participate in levodopa's antiparkinsonian action and levodopa-induced dyskinesias. We examined the functional status of the D(1) receptor in brain of patients with Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). Dopamine-stimulated adenylyl cyclase activity was significantly increased in putamen (+43%) and frontal cortex (+52%) in PD, normal in PSP, but decreased by 47% in putamen in MSA. The supersensitive dopamine D(1) receptors in both striatum and cerebral cortex in PD might compensate for dopamine deficiency, but could also contribute to long-term complications of levodopa therapy.
Tong
Junchao
J
Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health, Toronto, Canada. junchao_tong@camh.net
Fitzmaurice
Paul S
PS
Ang
Lee Cyn
LC
Furukawa
Yoshiaki
Y
Guttman
Mark
M
Kish
Stephen J
SJ
D000262:Adenylyl Cyclases / Q000378:metabolism*; D000368:Aged; D000369:Aged, 80 and over; D001921:Brain / Q000378:metabolism* / Q000473:pathology; D004298:Dopamine / Q000378:metabolism; D004789:Enzyme Activation / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000503:physiopathology*; D010300:Parkinson Disease / Q000503:physiopathology*; D017447:Receptors, Dopamine D1 / Q000378:metabolism*; D013494:Supranuclear Palsy, Progressive / Q000503:physiopathology*
D017447:Receptors, Dopamine D1; D000262:Adenylyl Cyclases; D004298:Dopamine